Trevi Therapeutics (TRVI) vs Xeris Biopharma (XERS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Trevi Therapeutics (TRVI) has outperformed Xeris Biopharma (XERS) over the past year, gaining 30.6% versus a gain of 24.3%. Over five years, TRVI leads with a +894.2% price change compared with +409.5% for XERS. Xeris Biopharma is the larger company by market cap ($1.86 billion vs $1.83 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TRVI | XERS |
|---|---|---|
| Share price | $12.83 | $10.19 |
| Market cap | $1.83B | $1.86B |
| 1-day change | -2.40% | +0.79% |
| YTD return | +2.44% | +29.81% |
| 1-year return | +30.60% | +24.27% |
| 5-year return | +894.19% | +409.50% |
| Forward P/E | — | 27.54 |
| EPS (TTM) | $-0.35 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $291.85M |
| Revenue growth (YoY) | — | +43.72% |
| Net income (latest FY) | $-42.76M | $554.00K |
| Gross margin | — | 85.41% |
| Operating margin | — | 8.53% |
| Net margin | — | 0.19% |
| 52-week high | $20.22 | $11.33 |
| 52-week low | $9.28 | $5.25 |
| Distance from 52-week high | -36.57% | -10.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +119.73% | +26.20% |
| Average volume | 1.95M | 2.17M |
| Shares outstanding | 142.48M | 182.32M |
| Employees | 34 | 435 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Trevi Therapeutics in Health Care and Xeris Biopharma in Healthcare.
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Xeris Biopharma
XERS stock →Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Healthcare · Drug Manufacturers - Specialty & Generic · 435 employees
TRVI vs XERS FAQ
Which is bigger, Trevi Therapeutics or Xeris Biopharma?
Xeris Biopharma (XERS) is larger, with a market capitalization of $1.86B compared with $1.83B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, TRVI or XERS?
TRVI returned +30.60% over the past 12 months, compared with +24.27% for XERS (price return, excluding dividends). Past performance does not predict future results.
Are Trevi Therapeutics and Xeris Biopharma in the same industry?
No. Trevi Therapeutics is in the Health Care sector, while Xeris Biopharma is in Healthcare.